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INTRODUCTION
Homozygous β-thalassemia results in absent or decreased
synthesis of the human β-globin chain. Patients with this
disorder have ineffective erythropoiesis, hemolytic anemia,
and hypochromic microcytic anemia. The only curative
therapy available is allogeneic bone marrow (BM) transplan-
tation. Most transplantation regimens for thalassemia to
date have involved myeloablation. This procedure has a
signiﬁcant risk of morbidity and mortality for those patients
who are fortunate to have a histocompatible donor. It has
been demonstrated that achievement of mixed chimerism
can be sufﬁcient to attain high hemoglobin A concentrations
in thalassemia patients [1-4]. Two patients with thalassemia
who achieved mixed chimerism had corrected anemia and
required no transfusion therapy [1].
Gene therapy, the replacement of normal human β- or
γ-globin genes into the hematopoietic stem cells of patients
with this disorder, is a promising therapy. High-level lineage-
speciﬁc stable β- or γ-globin expression in transduced cells
reinfused into patients in an autologous setting could be
curative, if successful. High-level long-term expression of a
transferred human β-globin gene has been reported in a
syngeneic mouse model after full myeloablation [5,6]. The
ability of these cells to engraft with a nonmyeloablative
preparative regimen is a desirable alternative to complete
marrow ablation, especially in children.
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ABSTRACT
Gene therapy, the replacement of normal human β- or γ-globin genes into the hematopoietic stem cells of
patients with homozygous β-thalassemia, is a promising therapy for the future. High-level lineage-specific stable
globin expression in transduced cells reinfused into patients in an autologous transplantation setting could be
curative, if successful. Previous studies have shown high-level donor chimerism in nonmyeloablated non-
thalassemic hosts. We have now studied the conditions for stable long-term engraftment of normal cells into a
thalassemia mouse model that lead to high-level donor chimerism and correction of the abnormal phenotype.
Thalassemic female mice treated with 0 to 300 cGy whole-body irradiation received transplantations of donor
cells harvested from wild-type males. Engraftment of male cells was quantitated by Y-chromosome polymerase
chain reaction analysis of blood and marrow progenitors, and changes in hemoglobin levels, red cell morphology,
and spleen size were measured at various times posttransplantation. High-level stable donor cell engraftment was
achieved in mice given 200 cGy and receiving transplants of 2 × 107 or more donor cells. The anemia, abnormal
peripheral blood smears, and splenomegaly improved in the thalassemic mice that had successful engraftment.
These studies demonstrate that stable and successful levels of engraftment of normal cells can correct the tha-
lassemic phenotype without fully myeloablating the host. This animal model should allow us to test the amount
of cytoreduction required and the level of engraftment and β-globin expression needed in autologous transplanta-
tion of β-globin gene-transduced cells to correct the abnormal phenotype in thalassemic mice, and it may be rele-
vant to human clinical trials, as well.
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Myeloablation is not required for successful engraft-
ment into host mice [7,8]. Ramshaw et al. demonstrated
that a single infusion of 2 × 108 male mouse cells injected
into nonmyeloablated female mice resulted in engraftment
levels up to 50% [9]. There was a quantitative relationship
between the donor cell dose required and the level of
engraftment achieved in mice who received no precondi-
tioning [10]. In myeloablated T-cell–depleted allogeneic
murine transplantations, decreasing lymphocyte and ery-
throcyte lineage engraftment is also reported with
decreasing donor cell dose. However, red cell engraftment
has been more easily achieved than has lymphocyte
engraftment [11].
Stewart et al. showed that nonmyeloablative doses of
irradiation at 50 to 100 cGy in the BALB-C wild-type
mouse can lead to high levels of donor chimerism with 10 to
40 × 106 donor cells [12]. Competitive repopulation of mar-
row with donor marked cells is also possible even in non-
myeloablated recipient mice and dogs [13-15].
We now show stable consistent engraftment with
high-level donor chimerism and correction of the tha-
lassemia phenotype by infusing unmanipulated wild-type
C57Bl/6J donor cells into a thalassemia mouse model [16].
The submyeloablative doses of radiation used to achieve
successful engraftment of donor cells and to correct the
thalassemia phenotype in these mice will potentially be
applicable to the successful engraftment of gene-transduced
cells in mouse β-thalassemia autotransplantation regi-
mens. This animal model may also be relevant to defining
the amount of cytoreduction, the number of transduced
cells required, and the level of β-globin expression needed
in autologous transplantation of β-globin gene-transduced
cells to correct the defect in human β-thalassemia
patients.
MATERIALS AND METHODS
Mice
Thalassemic Hbb° Hbbs mice [16] were back-crossed
with C57BL/6J wild-type mice for 10 generations to estab-
lish congenic lines [17]. Progeny were screened for the tha-
lassemia phenotype at approximately 4 to 6 weeks of age.
The thalassemia genotype was documented by polymerase
chain reaction (PCR) analysis of mouse tail DNA using
oligonucleotide primers that distinguished the normal and
mutated β-globin alleles. The primers used were a common
forward primer for both alleles, 5′-GAGCAATGTGGACA
GAGAAGGAG-3′, and 2 different reverse primers: TGAA
GAGCTTGGCGGCGAATGGG-3′ for the mutant allele
and 5′-TGATGTCTGTTTCTGGGGTTGTG-3′ for the
wild-type allele. After hematoxylin and eosin staining, blood
smears were examined for the presence of characteristic
changes associated with murine thalassemia: aniso and poik-
ilocytosis and microcytic, hypochromic red cells.
Thalassemia males were mated with wild-type females
to expand the C57Bl/6J,Hbb° Hbbs mouse colony. Four- to
6-week-old thalassemia females were used as recipients in
the experiments; 10- to 12-week-old wild-type males were
donors [18]. All mice were housed in a barrier facility.
Peripheral blood (PB) smears were analyzed at 2, 4, and
6 months posttransplantation to determine if correction of
the thalassemia phenotype had occurred. Hemoglobin levels
were measured as described [19].
BM Transplantation
Recipient females were treated with 0 to 300 cGy γ-
irradiation from a cesium source (Gamma Cell –40; Atomic
Energy of Canada, Ottawa, Canada) at a dose rate of 100
cGy/min. Donor male C57Bl/6J wild-type mice 10 to 12
weeks of age (The Jackson Laboratory, Bar Harbor, ME) were
killed by cervical dislocation. BM was harvested from tibias
and femurs as previously described [20]. Cell suspensions were
ﬁltered through Spectra/Mesh nylon 20 µm ﬁlter (Spectrum
Laboratories, Laguna Hills, CA) to remove any bone particles
and other debris. Cells were counted and resuspended at an
appropriate concentration in α minimal essential medium
(αMEM; Life Technologies, Rockville, MD). Recipient female
thalassemia mice were injected with 1 × 106 to 1 × 108 fresh
male BM cells via tail vein injection.
Analysis of PB DNA
Approximately 100 µL of PB from each mouse was col-
lected in 2 to 3 EDTA-lined capillary tubes. PB DNA was
Figure 1. Experimental design. Marrow was harvested from wild-type
male C57Bl/6J mice. Female thalassemia mice were given between 0
and 300 cGy of radiation and received transplants of between 1 × 106
and 1 × 108 male donor cells. Blood was collected by tail vein bleed and
analyzed at 2, 4, and 6 months posttransplantation for Y-chromosome
sequences by PCR, hemoglobin levels, blood smear morphology, and
hematopoietic progenitor colonies.
Nonmyeloablative Transplantation in Thalassemia
455B B & M T
isolated using the Isoquick Nucleic Acid Extraction Kit
(ORCA Research, Bothell, WA). DNA was quantitated by
spectrophotometry. PCR reactions for Y-chromosome
sequences were carried out on 1 µg of each PB DNA sample
as previously described for screening for engraftment of
male donor cells [21].
Clonogenic Assays
At varying times posttransplantation, 2 to 3 heparin-
treated hematocrit tubes of PB were collected by tail vein.
BM was obtained from long bones after mice were killed.
Blood volumes were brought to 1 mL with phosphate-
buffered saline. Samples were layered on 0.5 mL histopaque
1077 (Sigma, St. Louis, MO) and spun at 400g (2500 rpm in
an Eppendorf centrifuge). The mononuclear cell layer was
removed and washed in αMEM. Cells were resuspended in
0.3 mL of αMEM and added to 3 mL of methoCult GF
(Stem Cell Technologies, Vancouver, Canada) containing
interleukin (IL)-3, IL-6, stem cell factor, and erythropoietin
for the support of murine clonogenic progenitor colonies.
Half the cell suspension was placed with a 3-mL syringe and
a blunt 16-gauge needle on each of two 35-mm gridded
plates. Methylcellulose was spread evenly over the dish, and
the plates were incubated at 37°C in 5% CO2. Individual
colonies were picked 8 to 12 days after plating. DNA from
the individual colonies was prepared using Instagene Matrix
(BioRad, Hercules, CA).
PCR Analysis of Progenitor Colony DNA
For determination of the percent of male donor origin,
PCR reactions for Y-chromosome sequences were carried out
on 25 µL of each PB- or BM-derived colony sample as previ-
ously described [21]. All methylcellulose colonies negative for
Y-chromosome sequences were also analyzed for the presence
Table 1. Donor Cell Engraftment after Radiation*
Engraftment†
No. of Cells Transplanted 2 mo (Blood) 4 mo (Blood) 6 mo (Blood)
Group 1 (no radiation)‡ 5 × 106 0/2 0/2 0/2
1 × 107 0/3 0/3 0/3
2 × 107 0/3 0/3 0/3
5 × 107 0/2 0/2 0/2
1 × 108 1/2 1/2 1/2
Group 2 (100 cGy)
2a 2 ×107 0/4 0/4 0/4
0/4 = (0%)
2b 5 × 107 2/5 ND 1/5
2c 5 × 107 1/3 1/3 1/3
2d 5 × 107 6/10 5/9 0/9
2/17 = (11.8%)
2e 1 × 108 4/4 4/4 4/4
2f 1 × 108 3/3 3/3 3/3
7/7 = (100%)
Group 3 (200 cGy)
3a 1 × 107 0/5 ND 0/5
0/5 = (0%)
3b 2 × 107 4/5 4/5 3/4
3c 2 × 107 3/5 2/5 2/5
5/9 = (55.6%)
3d 5 × 107 4/5 4/5 3/4
3/4 = (75%)
Group 4 (300 cGy)
4a 1 × 106 1/6 1/6 1/6
1/6 = (16.6%)
4b 5 × 106 4/5 4/5 4/5
4c 5 × 106 5/6 3/6 3/6
7/11 = (63.6%)
4d 1 × 107 5/6 1/6 1/6
4e 1 × 107 1/6 1/6 1/6
4f 1 × 107 3/5 3/5 3/5
5/17 = (29.4%)
4g 2 × 107 1/1 1/1 1/1
1/1 = (100%)
*Y-chromosome PCR analysis of PB sample.
†No. of mice from each group who were Y positive by PCR/total mice.
‡Each line represents a cohort of mice in an individual experiment.
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of platelet-derived growth factor (PDGF) DNA using speciﬁc
primers to test for the presence of adequate DNA in the sam-
ples [21]. Samples negative in both the Y chromosome PCR
and the PDGF PCR were not included in calculating the
chimerism of each mouse from progenitor colony data.
RESULTS
Initially, 33 mice were screened for the thalassemia phe-
notype through PCR analysis of tail DNA as described in
Methods and by examination of the PB smears. The correla-
tion between the PCR-determined thalassemia genotype and
an abnormal PB smear was 100%; therefore, subsequently
only the PB smear was examined to determine the genotype
(data not shown).
The optimal combination of donor cell dose and host
irradiation needed to achieve stable engraftment and the
correction of the thalassemia phenotype in a thalassemia
mouse model was established as follows. C57BL/6J,
Hbb°Hbbs female thalassemia mice (described in Materials
and Methods) receiving from no irradiation to 300 cGy
received transplants of between 1 × 106 and 1 × 108 har-
vested C57BL/6J male BM cells. The mice were analyzed at
different time points posttransplantation for evidence of
male engraftment, hemoglobin levels, red cell morphology
on PB smear, and level of chimerism (Figure 1).
The female thalassemia mice that received transplants
were divided into 4 groups that received no radiation, 100
cGy, 200 cGy, or 300 cGy, and then were infused with dif-
ferent numbers of fresh male C57BL/6J BM cells. Mice
that received transplants were screened for donor cell
engraftment by Y-chromosome analysis of PB DNA (Table
1). At 1 to 2 months posttransplantation, mice were further
studied by quantitation of Y-chromosome–positive PB
colonies in the methylcellulose assay (Tables 2 and 3). At 4
and 6 months posttransplantation, this assay was performed
on mice that were Y-chromosome–positive by the PB PCR.
Hemoglobin levels were measured in a subset of mice
(Table 4). Red cell morphology data are presented for only
these mice, although red cell morphology was examined for
all mice at all time points (data not shown). Some of the
mice were further studied by methylcellulose assay of BM
progenitors and by measurement of spleen size (Table 3,
Figure 2).
Long-term engraftment by male donor cells was deﬁned
by reversion of the blood smear to normal, an increase in
the hemoglobin level toward normal, and evidence of
engraftment of donor cells 6 months posttransplantation.
One of 2 mice with transplants of 1 × 108 male cells after no
irradiation showed some level of donor cell engraftment
long-term, whereas no mice in the no-irradiation group that
received transplants of less than this number of cells
engrafted (Table 1, group 1). In mice that received 100 cGy,
1 × 108 cells was the minimal cell dose required to achieve
long-term engraftment (Table 1, group 2). This result was
significant when compared to results of mice in the same
group that received 2 × 107 to 5 × 107 donor cells (Table 1,
P < .001, 2-tailed Student t test). However, 1 × 108 cells is
equivalent to the cell number obtained from marrow har-
vested from the femurs and tibias of 2 mice in our labora-
tory (or the approximate total number of marrow cells in
Table 2. PCR Analysis of Methylcellulose Colonies from PB*
Group (Radiation) and Cell Dose Mouse 2 Mo† 4 Mo 6 Mo 
Group 1 (no radiation)
1 × 106–5 × 107 cells 1-8 0 0 0
1 × 108 cells 1 0/6 0/7 ND
2 ND ND 2/2
Group 2 (100 cGy)
2 × 107 cells
Experiment 2a 1-4 0 ND ND
5 × 107 cells
Experiment 2b 1-4 ND 0 0
5 ND ND 3/3
Experiment 2c 1-2 0 0 0
3 5/5 1/4 9/18
Experiment 2d 1-10 0 ND ND
1 × 108 cells
Experiment 2e 1-2 ND 0 0
3 ND 4/4 1/5
4 ND 1/1 3/6
Experiment 2f 1 2/2 7/14 2/11
2 4/5 4/5 7/12
3 1/3 2/2 3/16
Group 3 (200 cGy)
1 × 107 cells
Experiment 3a 1-4 ND ND 0
2 × 107 cells
Experiment 3b 1 0/14 ND ND
2 6/8 11/14 12/18
3 4/6 17/18 6/7
4 5/6 15/18 11/11
5 11/13 8/16 ND
Experiment 3c 1-3 0 ND ND
4 8/10 4/4 ND
5 8/11 2/3 ND
5 × 107 cells
Experiment 3d 1 0/21 ND ND
2 7/10 16/18 13/17
3 5/7 17/17 ND
4 5/8 12/16 ND
5 3/8 14/18 16/17
Group 4 (300 cGy)
1 × 106 cells
Experiment 4a 1-5 0/18 ND ND
6 9/12 15/18 5/5
5 × 106 cells
Experiment 4b 1-2 0 ND ND
3 17/18 14/18 15/16
4 0/17 3/14 5/17
5 16/17 6/10 9/12
6 3/4 11/18 8/10
Experiment 4c 1-3 0 ND ND
4 0/18 2/17 2/15
5 10/10 21/22 17/18
6 15/20 5/9 15/18
1 × 107 cells
Experiment 4d 1-5 0 ND ND
6 3/9 8/21 6/10
Experiment 4e 1-5 0/8 ND ND
6 16/18 18/18 18/22
Experiment 4f 1-2 0 ND ND
3 9/11 4/4 24/27
4 19/20 5/6 22/23
5 7/8 4/4 23/26
2 × 107 cells
Experiment 4g 1 11/12 5/6 17/24
* ND indicates not done.
†No. of Y-chromosome–positive colonies/total analyzed.
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1 whole mouse), an unrealistic number to extrapolate for use
in transplantation of gene-transduced cells.
When cytoreduction was increased to 200 cGy, stable
high-level donor cell engraftment was achieved in a majority
of mice that received transplants of 2 × 107 fresh wild-type
male cells (Table 1, group 3). With 200 cGy, 1 × 107 cells
were inadequate to achieve engraftment compared to 2 × 107
donor cells (P < .001, Table 1). For mice given 300 cGy of
irradiation, 5 × 106 cells established stable engraftment
(Table 1, group 4). Four of 6 mice that received transplants
in one experiment under these conditions showed stable
engraftment at 6 months. When 1 × 107 cells were infused
in another experiment, 3 of 5 mice showed stable donor cell
engraftment. The results of these latter experiments were
more variable in 2 other experiments using the same cell
dose and radiation, and there was no statistically signiﬁcant
difference in engraftment of mice transfused with 5 × 106
versus 1 × 107 donor cells after 300 cGy irradiation. (P > .05,
Table 1). In summary, these results suggest that feasible
numbers of corrected cells can be used in nonmyeloablative
autotransplantation protocols.
Control mice that received 200 cGy and 300 cGy of
radiation but no rescue of male cells showed no major toxic-
ity from the radiation. They continued to thrive and exhib-
ited the expected life span when compared to the control
group receiving no irradiation (data not shown).
We quantitated the level of donor cell engraftment that
the mice achieved at different donor cell doses posttransplan-
tation by analyzing individual progenitor colonies in methyl-
cellulose by PCR for Y-chromosome sequences (see Methods).
The presence of DNA for Y-chromosome–negative colonies
was conﬁrmed by PCR for PDGF (data not shown). After 2
months posttransplantation, only those mice that showed
donor cell engraftment by PB Y-chromosome analysis (Table
1) were analyzed further for the extent of chimerism (Tables 2
and 3). All mice that showed donor cell engraftment also had
persistent high-level chimerism ranging from 50% to 100% at
6 months posttransplantation (Tables 2 and 3). Some mice
showed a faint Y band in PB analysis at 1 to 2 months, but
they showed no change in phenotype by morphology and 0%
chimerism when progenitor colonies were analyzed. These
mice had lost the Y band in the PB PCR by 4 months; this loss
was presumably due to inadequate numbers of donor stem
cells engrafted. Figure 3 shows a typical Y-chromosome PCR
analysis of individual methylcellulose colonies from a repre-
sentative mouse that showed engraftment of male cells.
We also measured male donor cell engraftment in BM
progenitors 1 to 2 years posttransplantation in some mice
(Table 3). There was an excellent correlation between engraft-
ment of male donor PB progenitors at 6 months and BM pro-
genitors in the same mice killed at later times (Table 3). The
results indicate that measurement of PB progenitors in
methylcellulose at 6 months is an excellent predictor of long-
term marrow stem cell engraftment.
Hemoglobin levels, engraftment status, and PB smears of
mice from the 4 different groups were examined posttrans-
plantation (Table 4). Donor cell engraftment (Y-chromosome–
positive progenitor data) was measured 6 months posttrans-
plantation. The hemoglobins and PB smears were measured
2 to 20 months posttransplantation in different animals. The
hemoglobin levels postengraftment in mice successfully
Table 3. Comparison of Long-term Engraftment of PB and Marrow 
Progenitors
Mouse Treatment PB (6 Mo)* BM Progenitors Mo†
1 200 cGy, 2 × 107 cells 100%‡ (11/11) 95.6% (22/23) 24
2 200 cGy, 5 × 107 cells 76.5% (13/17) 77.8% (14/18) 24
3 300 cGy, 1 × 106 cells 100% (5/5) 47.8% (11/23) 11
4 300 cGy, 5 × 106 cells 94.4% (17/18) 88.9% (16/18) 11
5 300 cGy, 5 × 106 cells 83.3% (15/18) 83.3% (20/24) 11
6 300 cGy, 1 × 107 cells 88.9% (24/27) 95.5% (21/22) 17
7 300 cGy, 1 × 107 cells 88.5% (23/26) 82.6% (19/23) 17
8 300 cGy, 1 × 107 cells 60% (6/10) 70% (14/20) 11
9 300 cGy, 2 × 107 cells 70.8% (17/24) 66.7% (16/24) 17
*PB progenitor assay results, 6 mo posttransplantation.
†Mo posttransplantation for BM progenitor assay (mice killed).
‡% of progenitors positive for Y chromosome by PCR (no. pro-
genitors Y-chromosome–positive by PCR/total no. of progenitors).
Table 4. Phenotypic Changes*
Mouse, Radiation Dose, Hemoglobin Engraftment PB
and Cell Dose Level, g/dL Status Smear
Wild-type C57Bl/6J 15.6 N
Thalassemia control 11.6 Ab
Thalassemia control 9.5 Ab
Group 1 (no radiation)
2 × 107 cells 6.7 NE Ab
10.7 NE Ab
5 × 107 cells 8.8 NE Ab
9.9 NE Ab
Group 2 (100 cGy)
2 × 107 cells 10.2 NE Ab
9.9 NE Ab
10.2 NE Ab
11.6 NE Ab
5 × 107 cells 12.6 NE Ab
1 × 108 cells 13.0 E N
14.2 E N
Group 3 (200 cGy)
1 × 107 cells 9.3 NE Ab
2 × 107 cells 7.6 NE Ab
14.9 E N
15.4 E N
14.6 E N
14.9 E N
13.7 E N
14.6 E N
5 × 107 cells 15.6 E N
16.0 E N
14.7 E N
12.0 NE Ab
Group 4 (300 cGy)
1 × 106 cells 10.1 NE Ab
9.0 NE Ab
5 × 106 cells 8.6 NE Ab
9.9 E Ab
14.6 E N
1 × 107 cells 13.1 E N
14.2 E N
2 × 107 cells 15.6 E N
*N indicates normal smear; Ab, anisopoikilocytosis, microcytosis,
and target cells; NE, not engrafted; E, engrafted.
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engrafted with donor male cells were in the range of 13 to
16 g/dL, similar to the hemoglobin levels of the C57Bl/6J
wild-type mice (Table 4). The thalassemia mice that did not
achieve engraftment with donor male cells showed a persis-
tent anemia with hemoglobin levels of 6 to 12 g/dL, similar
to the levels measured in thalassemia control mice. The
results were consistent, and all mice that achieved engraft-
ment showed an improved hemoglobin level (Table 4).
PB smears of the mice were analyzed pre- and posttrans-
plantation. As illustrated in panels 1a and 2a of Figure 4, the
thalassemia phenotype is characterized by aniso and poikilo-
cytosis, numerous microcytic and hypochromic erythrocytes,
and target cells. The smears from the female mice that
demonstrated high-level stable male cell engraftment as
illustrated in panels 1b and 2b of Figure 4 show a more
homogenous red cell pattern with normocytic red blood
cells, loss of target cells, and reduced anisopoikilocytosis. As
shown in Table 4 and Figure 5, only those mice that achieved
stable high-level donor male cell engraftment had a changed
phenotype as well as normal hemoglobin levels and normal-
ization of the PB smear. The originally enlarged spleens
were reduced in size or returned to normal size in the mice
with successful engraftment (Figure 2).
The results indicate that high-level long-term stable
engraftment of normal donor syngeneic cells and reversion
of the thalassemia phenotype can be achieved with small
Figure 2. The spleens of normal, thalassemic, and transplant-uncorrected
and corrected mice are shown. From top to bottom, spleens of: A, nor-
mal C57Bl/6J mouse; B, thalassemic mouse; C and D, posttransplanta-
tion corrected mice; E and F, posttransplantation uncorrected mice.
Figure 3. Y-chromosome PCR analysis of mice that received transplants. The results are from group 4, experiment 4f mice given 300 cGy radiation dose
and 1 × 107 donor cells (Tables 1 and 3). The arrows indicate the expected 720 base pair band PCR product using Y-chromosome–speciﬁc primers. A,
4-month analysis of PB (Table 1). Lanes 1 through 5 represent individual mice. B, 6-month analysis of the mice in A (Table 1). C, PCR analysis of
methylcellulose colonies from PB of mouse 5 from group 4, experiment 4f at 6 months (Table 3). Lanes 1 through 26 represent individual colonies.
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doses of radiation in thalassemic mice. We obtained consis-
tent long-term correction of the thalassemia phenotype
when 2 × 107 unmanipulated fresh BM cells were infused
after a single dose of 200 cGy, or with 5 × 106 to 1 × 107
cells after 300 cGy. These combinations of a relatively low
dose of donor cells and a relatively low level of irradiation
seem optimal.
DISCUSSION
Successful engraftment of allogeneic stem cells or
genetically transduced autologous stem cells in a nonmye-
loablative setting is a desirable therapeutic option for
patients with β-thalassemia or sickle cell disease. In a recent
human clinical trial, Cavazzana-Calvo et al. reported that
gene-corrected donor stem cells in severe combined
immunodeﬁciency–XI patients who received no condition-
ing regimen engrafted and corrected the immune deﬁciency
of 2 patients. The corrected cells had a selective advantage
over the host untransduced stem cell population [22]. This
advantage resulted in engraftment of a functional expanded
gene-corrected mature lymphocyte population [22].
Autologous transplantation after transfer of a normal
β-globin gene into hematopoietic stem cells is a major ther-
apeutic goal. Kittler et al. demonstrated about 9% long-
term engraftment of syngeneic retrovirally transduced BM
cells into nonmyeloablated mice [23]. More recently, the
successful engraftment and expression of human β-globin
genes in fully myeloablated thalassemic mice has been
reported with correction of the phenotype [6].
The ultimate goal is to correct the anemia of these
animals with the engraftment of autologous stem cells trans-
duced with and expressing normal β-globin genes in a non-
myeloablative setting. We back-crossed our β-thalassemia
mice into the C57Bl/6J background and established the con-
ditions for engraftment of wild-type C57Bl/6J marrow cells
that would correct the thalassemia phenotype of these mice:
the donor normal cell dose required and the dose of irradia-
tion. Our hope is to apply this model to the engraftment
and expression of autologous thalassemia mouse stem cells
transduced with and expressing the normal β-globin gene.
We found that infusion of 1 × 108 cells established high-
level engraftment and correction of phenotype after no
preparative therapy or 100 cGy of irradiation. This, however,
was an unrealistically large cell dose to be extrapolated to
gene transduction experiments or to be applied to human tri-
als. By increasing the radiation from 100 cGy to 200 cGy, still
a nontoxic dose of irradiation for the mouse, we were able to
decrease the number of wild-type donor cells to 2 × 107 cells.
Using these conditions, we see consistent high-level engraft-
Figure 4. PB smears of thalassemia mice before and after transplantation. 1a, Thalassemia mouse pretransplantation. 1b, Mouse in 1a posttrans-
plantation, 100 cGy and 1 × 108 donor cells. 2a, Thalassemia mouse pretransplantation. 2b, Mouse in 2a posttransplantation, 100 cGy and 1 × 108
donor cells. Similar changes in smears were seen in all successfully donor cell–engrafted mice.
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ment and achieve high-level long-term chimerism of 80% to
100% normal cells, 6 to 24 months posttransplantation
(Tables 2 and 3). All of the mice with successful engraftment
had corrected anemia as demonstrated by normalized hemo-
globin levels and improved PB smears (Table 4).
There are only limited parallels between the essentially
autologous transplantation protocol in mice that we describe
in this paper and the conditions that may be used in autolo-
gous transplantations with gene therapy in humans. Cur-
rently, 200 cGy total body irradiation plus immunosuppres-
sive agents are required in nonmyeloablative allogeneic
transplantations in humans to achieve long-term stable
engraftment with an average donor cell dose of 5 × 106
CD34+ cells/kg [24]. A successful autologous globin gene
therapy transplantation regimen should not require the use
of immunosuppressive agents to achieve engraftment
because there should be no graft rejection or graft-versus-
host disease, possibly permitting a less ablative regimen to be
used, as well.
We conclude that stable and successful levels of engraft-
ment of normal cells that could correct the thalassemia phe-
notype can be achieved in a β-thalassemia mouse model
using a reasonable nonmyeloablative regimen. This animal
model should allow us to test the amount of cytoreduction
required and the level of engraftment and β-globin expres-
sion needed to correct the abnormal phenotype in an autol-
ogous transplant setting with β-globin gene-transduced
cells. These data may also be useful in determining the opti-
mal nonmyeloablative regimen required for thalassemia
patients in an autotransplantation setting with β-globin
gene-transduced cells.
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